Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form
Projects
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked, three-group, two-year study evaluating the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema,
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Multicenter, randomized, double-masked, controlled, phase III study with active comparator to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (DME),
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Multiple-dose, randomized, active-controlled, patient- and investigator-masked proof-of-concept study of intravitreal LAK651 in patients with diabetic macular edema,
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Observational, transversal, retrospective and multicenter study to evaluate the burden of disease in patients with neovascular macular degeneration associated with age in Spain (AMD-MANAGE),
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
EPA
-
Ophthalmology
Researcher
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Randomized, double-masked, placebo-controlled and exploratory trial to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1467335 administered orally for 12 weeks with a 12-week follow-up period in patients with non-proliferative diabetic retinopathy without macular edema central predominance diabetic
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
-
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Multiple-dose, randomized, active-controlled, patient- and investigator-masked proof-of-concept study of intravitreal LAK651 in patients with diabetic macular edema,
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
RD2015
-
- Year 2018
- Dos de Maig Hospital Integral Care Center
Randomized, double-masked, placebo-controlled and exploratory trial to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1467335 administered orally for 12 weeks with a 12-week follow-up period in patients with non-proliferative diabetic retinopathy of central predominance
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
-
- Year 2018
- Comprehensive Care Center Dos de Maig Hospital
Observational, transversal, retrospective and multicenter study to evaluate the burden of disease in patients with neovascular macular degeneration associated with age in Spain (AMD-MANAGE),
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
EPA
-
- Year 2018
- Dos de Maig Hospital Integral Care Center
Observational, transversal, retrospective and multicenter study to evaluate the burden of disease in patients with neovascular macular degeneration associated with age in Spain (AMD-MANAGE),
-
DISTRICT ATTORNEY:
Novartis Farmacéutica, SA
-
TYPE E:
EPA
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
